Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins by Mamat, Uwe et al.
Mamat et al. Microbial Cell Factories  (2015) 14:57 
DOI 10.1186/s12934-015-0241-5RESEARCH Open AccessDetoxifying Escherichia coli for endotoxin-free
production of recombinant proteins
Uwe Mamat1*, Kathleen Wilke1, David Bramhill2,12, Andra Beate Schromm3, Buko Lindner4, Thomas Andreas Kohl5,
José Luis Corchero6,7,8, Antonio Villaverde7,8,6, Lana Schaffer9, Steven Robert Head9, Chad Souvignier2,
Timothy Charles Meredith10 and Ronald Wesley Woodard11Abstract
Background: Lipopolysaccharide (LPS), also referred to as endotoxin, is the major constituent of the outer leaflet
of the outer membrane of virtually all Gram-negative bacteria. The lipid A moiety, which anchors the LPS molecule
to the outer membrane, acts as a potent agonist for Toll-like receptor 4/myeloid differentiation factor 2-mediated
pro-inflammatory activity in mammals and, thus, represents the endotoxic principle of LPS. Recombinant proteins,
commonly manufactured in Escherichia coli, are generally contaminated with endotoxin. Removal of bacterial
endotoxin from recombinant therapeutic proteins is a challenging and expensive process that has been necessary
to ensure the safety of the final product.
Results: As an alternative strategy for common endotoxin removal methods, we have developed a series of E. coli
strains that are able to grow and express recombinant proteins with the endotoxin precursor lipid IVA as the only
LPS-related molecule in their outer membranes. Lipid IVA does not trigger an endotoxic response in humans typical
of bacterial LPS chemotypes. Hence the engineered cells themselves, and the purified proteins expressed within
these cells display extremely low endotoxin levels.
Conclusions: This paper describes the preparation and characterization of endotoxin-free E. coli strains, and
demonstrates the direct production of recombinant proteins with negligible endotoxin contamination.
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In the last thirty years, the biopharmaceutical industry
has brought more than 220 biologics to market, giving
rise to sales of approximately $70 - $80 billion per year
[1]. One third of the unique recombinant protein thera-
peutics [2] and approximately one half of all products
approved [3] are produced using an Escherichia coli
based expression platform. However, the outer membrane
of E. coli, like that of most Gram-negative bacteria, con-
tains the potent immunostimulatory molecule lipopolysac-
charide (LPS). In mammalian hosts, LPS (also known as
endotoxin) can induce a pyrogenic response and ultim-
ately trigger septic shock. Contaminating LPS must there-
fore be removed from recombinant therapeutic proteins* Correspondence: umamat@fz-borstel.de
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unless otherwise stated.expressed in E. coli before they can be safely adminis-
tered to human patients. The removal of endotoxin from
recombinant therapeutics and the testing to demonstrate
endotoxin levels below a minimal threshold requires con-
siderable effort, adding significant developmental and
manufacturing costs. To date, no post-expression method-
ologies have been described that can remove endotoxin en-
tirely [4]. Common endotoxin removal methods, such as
ultrafiltration, Triton X phase separation, anion-exchange
chromatography, adsorption on activated carbon, or treat-
ment with polymyxin B- or histamine-immobilized affinity
resins, are plagued by low efficiency and unsatisfac-
tory selectivity [5]. In this context, it is important to
note that commercially available recombinant proteins
manufactured in E. coli may contain residual endotoxin
in low but still sufficient quantities to activate human im-
mune cells [6].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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toxic response in mammals. LPS-mediated activation of
a cell-surface receptor, consisting of Toll-like receptor 4
(TLR4) complexed with myeloid differentiation factor 2
(MD-2), results in the production of pro-inflammatory
cytokines and type-1 interferons that are the chief effec-
tors of the endotoxic response [7]. Research relating the
structure of LPS to the activation of TLR4/MD-2 has
demonstrated that lipid A is the component of LPS that
is responsible for its TLR4/MD-2-dependent endotoxic
activity [8]. Alterations in the structure of lipid A, chiefly
modifications to the structure, number, and attachment
sites of the hydrophobic acyl chains to the di-glucosamine
backbone, significantly impacts endotoxic activity through
altering TLR4/MD-2 mediated signaling [9,10]. When all
the secondary acyl chains are removed, the under-acylated
lipid A precursor lipid IVA not only lacks endotoxic activ-
ity in human immune cells, but also becomes a hTLR4/
MD-2 receptor antagonist [8].
Until recently, it was believed that the structural features
of LPS required to maintain the integrity of the Gram-
negative outer membrane were essentially the same as the
structural features of LPS required to elicit an endotoxic
immune response in mammalian cells. The minimal struc-
ture essential for survival of typical laboratory strains of
E. coli K-12 was thought to consist of a molecule of lipid
A glycosylated at the 6′ position with two 3-deoxy-D-
manno-oct-2-ulosonic acid (Kdo) sugar residues. This
view changed when we reported the construction and
characterization of KPM22, a derivative of the E. coli K-12
wild-type strain BW30270 that is unable to synthesize
Kdo and yet retains viability with lipid IVA as the predom-
inant outer membrane LPS component [11]. Subsequent
research identified gain of function suppressor mutations
in the LPS transport apparatus that apparently promote
flipping of lipid IVA across the inner membrane [12].
These mutations both remove toxic side effects normally
associated with lipid IVA accumulation in the inner mem-
brane as well as provide a sufficient concentration of lipid
IVA to support outer membrane biogenesis. The discovery
of KPM22 presented us with the opportunity to construct
recombinant protein expression strains of E. coli with low
intrinsic endotoxic potential by rationally reprogramming
the outer membrane biosynthesis pathway to elaborate
solely lipid IVA.
This report describes the construction of stable E. coli
strains, including derivatives of the popular expression
strain BL21 (DE3), capable of efficiently expressing recom-
binant proteins which are essentially free of endogenous
endotoxin contamination under standard laboratory con-
ditions. To evaluate the utility of this expression platform,
we applied it to the production of two different human
proteins: apolipoprotein A-1 (ApoA-1) and heat shock
protein 70 (Hsp70), both known to avidly bind endotoxin,and demonstrate marked reduction in endotoxin activity
from minimally purified recombinant proteins.
Results and discussion
Engineering of LPS biosynthesis in E. coli
We began our construction of LPS-free E. coli K-12 using
the Kdo-depleted strain KPM22 L11 [12]. This strain
contains deletions of kdsD and gutQ, which encode D-
arabinose 5-phosphate isomerases essential for the bio-
synthesis of Kdo [13,14], and a C:G to T:A transition
at position 52 of msbA, which acts as a suppressor of the
normally lethal ΔKdo phenotype [12]. To produce a strain
that contains lipid IVA as the only LPS outer membrane
component and that cannot revert to synthesize endotoxic
derivatives, we sequentially generated mutant strains with
unmarked deletions of the genes lpxL, lpxM, pagP, lpxP
and eptA. These genes encode enzymes acting down-
stream of Kdo incorporation into lipid IVA, and are either
part of the constitutive pathway of Kdo2-hexaacyl lipid A
biosynthesis (the Kdo2-lipid IVA lauroyl-ACP acyltransfer-
ase LpxL and the Kdo2-lauroyl-lipid IVA myristoyl-ACP
acyltransferase LpxM), modify lipid A with additional acyl
chains (the phospholipid:lipid A palmitoyl transferase
PagP and the Kdo2-lipid IVA palmitoleoyl-ACP acyltrans-
ferase LpxP), or append phosphoethanolamine (P-EtN)
under certain conditions (the lipid A P-EtN transfer-
ase EptA) [15] (Figure 1). Analysis of the LPS isolated
from this strain, designated KPM318, using electrospray-
ionization Fourier-transformed ion cyclotron mass spec-
trometry (ESI FT-ICR) revealed a single primary peak at
1404.85 u, consistent with the structure of the unmodi-
fied tetraacyl-1,4′-bisphosphate LPS precursor lipid
IVA (Figure 2A).
The successful construction of KPM318 demonstrated
the viability of E. coli containing only lipid IVA. However,
like other E. coli K-12 strains with partially defective outer
membranes such as the ΔKdo prototype strain KPM22
[11], KPM318 displayed growth defects at temperatures
above 40°C. To overcome this, we isolated a series of
stable temperature-resistant derivatives of KPM318 cap-
able of growing exponentially at 42°C. KPM335 was the
most robust of the spontaneous mutants. Whole-genome
sequencing of KPM335 identified a single de novo muta-
tion in comparison to the temperature sensitive KPM318
parent strain, a G:C to T:A transversion at base number
181 of the frr gene (Additional file 1: Table S1). The frr
gene encodes an essential ribosome recycling factor which
has been described to play multiple cellular roles, such as
in disassembly of the post-termination complex [16], pre-
vention of translation errors [17], promoting translational
coupling [18], and increasing cell viability through poly-
amine stimulation of stationary-phase E. coli cultures [19].
The derivation of KPM335 argues strongly for a direct
correlation between the development of the frr181 allele
Figure 1 Biosynthetic reactions targeted during the construction of E. coli strains KPM318 and KPM404. The late acyltransferases LpxL and
LpxM of the constitutive pathway transfer laurate and myristate, respectively, to Kdo2-lipid IVA to form the characteristic acyloxyacyl units
of hexaacylated Kdo2-lipid A. In contrast, LpxP, PagP and EptA are regulated in response to certain stimuli such as incorporation of palmitoleate in
place of laurate by LpxP at low growth temperatures or PagP-catalyzed palmitoylation of lipid A upon phospholipid translocation to the outer leaflet
of the outer membrane, for example, in strains defective in LPS biosynthesis. The acyl-acyl carrier protein (ACP) serves as the preferred acyl donor for
various lipid A-acyltransferases.
Figure 2 Charge deconvoluted ESI FT-ICR mass spectra in negative ion mode of lipid IVA isolated from BW30270-derived mutants. The lipid IVA
(calculated mass 1404.854 u) was extracted from E. coli (K-12) strains KPM318 (A) and KPM335 (B). Mass numbers given refer to the monoisotopic
masses of neutral molecules. Peaks representing molecules with variations in acyl chain length are labeled with asterisks (Δm = 14.02 u). The
molecular ion at 1484.82 u in panel B indicates the presence of a minor fraction of 1-diphosphate lipid IVA. The structures of lipid IVA
and 1-diphosphate lipid IVA are shown as insets in panels A and B, respectively.
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at 42°C. However, elucidation of the underlying mechan-
ism must await further investigations.
ESI FT-ICR analysis of the LPS isolated from KPM335
revealed no significant changes in the LPS composition,
with lipid IVA remaining the predominant LPS-related
molecule as in the parent KPM318 strain (Figure 2B).
However, in contrast to KPM318, spectra of KPM335 dis-
played a minor peak with a molecular mass of 1484.82 u,
consistent with the structure of 1-diphosphate lipid IVA.
Touzé and coworkers have shown previously that transfer
of a second phosphate group to the 1 position of lipid A
is catalyzed by LpxT, an inner membrane protein of
the undecaprenyl-pyrophosphate phosphatase family,
which is able to phosphorylate Kdo2-lipid IVA in vitro,
but not lipid acceptors lacking Kdo [20]. Thus, the pres-
ence of a minor tris-phosphorylated lipid IVA fraction
in KPM335 argues against an absolute requirement of
LpxT for Kdo-glycosylated lipid A acceptors under in vivo
conditions. It remains unclear, however, why phosphoryl-
ation of lipid IVA, albeit with a very low efficiency, can
occur in KPM335, but apparently not in its KPM318 par-
ent strain.
Apart from the frr181 mutation in KPM335, a total of
12 mutations were specific to both KPM318 and KPM335,
including ΔkdsD, ΔgutQ, ΔlpxL, ΔlpxM, ΔpagP, ΔlpxP,
ΔeptA and msbA52 as a prerequisite for synthesis of lipid
IVA as the predominant LPS-related outer membrane
component. For another four mutations, we believe that
they arose spontaneously during the generation of mutant
strains, namely a silent mutation located in yqiI, two mis-
sense mutations in gor and waaY, and a point mutation in
the non-coding region upstream of the deleted eptA gene.
The latter mutation is most likely a result of KPM274 con-
struction as a donor strain of the ΔeptA::kan cassette. The
mutation is located within the sequence of the homology
region of primer ECOeptAH1 (Additional file 2: Table S2)
and suggests an error in PCR amplification of the kanamy-
cin resistance cassette targeting the eptA gene and ultim-
ately integration into the genome of KPM318. Compared
to the reference genome sequence of the common E. coli
MG1655 progenitor, the strains BW30270, KPM318 and
KPM335 share sequence variations at six locations. Of
these, both a silent nucleotide substitution at position 114
and a single nucleotide insertion at base number 253 of
ylbE, and deletion of nucleotide 151 within the glpR gene
have been described recently as genetic variations in com-
mon E. coli MG1655 stock cultures [21]. Furthermore,
while E. coli MG1655 has been shown to express a defect-
ive ribonuclease PH due to a frameshift by deletion of the
first nucleotide of codon 223 of the pseudogene rph-1
[22], insertion of a single nucleotide as the first base of
codon 224 of rph-1 predicts reconstitution of RNase PH
function and elimination of the polar effect of the rph-1mutation on the downstream pyrE gene in BW30270,
KPM318 and KPM335.
Next, we decided to replicate the unique set of un-
marked genomic deletions in the genetic background of
the popular E. coli expression strain BL21 (DE3). As a first
step towards the construction of an LPS-free E. coli BL21
(DE3) derivative, we replaced the wild-type msbA gene
with the msbA148 suppressor allele of strain KPM22 L1
[12]. This allowed the resulting strain, MWB03, to tolerate
null mutations in otherwise essential genes of the LPS
biosynthesis pathway. We then sequentially deleted the
same genes that had been deleted during the creation of
KPM318. Whole-genome sequencing of the final strain,
KPM404, confirmed the presence of the msbA148 sup-
pressor mutation (Additional file 3: Table S3), and verified
the absence of the kdsD, gutQ, lpxL, lpxM, pagP, lpxP and
eptA genes. In comparison to the genome sequence of
E. coli BL21 (DE3), we further identified a silent mutation
in yceJ, three missense changes within the coding se-
quences of YadG, ECD_00513 and RstA, and a point mu-
tation in the intergenic region between nudC and hemE.
Finally, a total of five single nucleotide substitutions were
counted in the region between nucleotides 46 and 222 of
the basR gene downstream of ΔeptA. These substitutions
perfectly matched the sites of basR sequence variations in
E. coli B and K-12, indicating that about one third of the
BasR-encoding gene of KPM404 was replaced by the cor-
responding basR sequence of E. coli K-12. Just as for the
construction of KPM318, the E. coli K-12 strain KPM274
served as the donor for transfer of the ΔeptA::kan cassette
via P1vir transduction to yield strain KPM403, which well
explains the generation of a basR hybrid sequence by co-
transduction of the ΔeptA::kan cassette and adjacent basR
sequences. In fact, as described above, the use of KPM274
as a ΔeptA::kan donor strain also explains why KPM404
carries a point mutation at the same position upstream of
the deleted eptA gene as in KPM318.
Mass spectrometric analyses of the LPS profiles from
mutants established in the BL21 (DE3) genetic background
underscored the need for radical modification of LPS bio-
synthesis to accomplish synthesis of only lipid IVA in
KPM404 (Figures 3 and 4). While disruption of the gutQ,
kdsD and lpxL genes in the intermediate mutant strain
KPM396 resulted in synthesis of non-glycosylated lipid
IVA precursors lacking the secondary lauroyl and myris-
toyl chains, mass spectrometry revealed a rather heteroge-
neous mixture of differently modified lipid IVA species.
The spectra displayed four prominent peaks with molecu-
lar masses of lipid IVA substituted with one P-EtN group
(1527.86 u), lipid IVA modified with two P-EtN moieties
(1650.87 u), and palmitoylated lipid IVA molecules carry-
ing either one (1766.09 u) or two (1889.10 u) P-EtN resi-
dues. Since lipid A palmitoylation seems to be an indication
for an adaptive response to aberrant translocation of
Figure 3 Charge deconvoluted ESI FT-ICR mass spectra in negative ion mode of LPS isolated from BL21 (DE3)-derived mutants. Mass numbers
given refer to the monoisotopic masses of neutral molecules. Peaks representing molecules with variations in acyl chain length are labeled with
asterisks (Δm = 14.02 u). The mass spectra depict the progress in elimination of lipid IVA heterogeneity by sequential deletion of genes encoding
the addition of acyl chains and P-EtN to the lipid A precursor.
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brane [23], we suspect that PagP-mediated transfer of
palmitate to lipid IVA is triggered by perturbations of outer
membrane lipid asymmetry in Kdo-depleted strains of the
KPM series. As shown for the LPS sample of KPM400,
complete loss of the palmitoylated lipid IVA fraction was
achieved by deletion of the pagP gene, leaving lipid IVA
molecules modified with either one or two P-EtN groups
unaffected.
Due to the block in Kdo biosynthesis and the lack of
LpxL, Kdo2-lipid IVA and Kdo2-(lauroyl)-lipid IVA, the
preferred substrates for LpxP and LpxM, respectively
[24-26], cannot be synthesized in strains derived from
KPM396. In addition, previous work has shown that ex-
pression of LpxP is induced under conditions of cold
shock (12°C) to incorporate an unsaturated C16:1 acyl
chain at the expense of a laurate (C12:0), perhaps reflect-
ing the demand to adjust membrane fluidity in the cold
[25,27]. It was therefore not surprising that deletion of
the lpxP and lpxM genes did not exhibit an obviouseffect on lipid IVA composition of KPM400 and KPM402,
respectively. There is no data indicating that LpxP and
LpxM are capable of using lipid IVA as an acceptor sub-
strate. It seems to be quite possible, however, that both en-
zymes show low levels of activity under specific conditions.
Contrary to the proposed physiological role of LpxP in
adaptation of E. coli cells to low growth temperatures, lim-
ited induction of LpxP expression has been demonstrated
as a potential compensatory mechanism even at 30°C in
lpxL and lpxL lpxM mutants of E. coli W3110 [28]. Like-
wise, LpxM was able to transfer a myristoyl chain directly
to Kdo2-lipid IVA in E. coli W3110 strains lacking lpxL and
lpxL lpxP [28].
Like PagP and LpxP, EptA-dependent modification of
lipid A with P-EtN is part of the complex regulatory net-
work associated with the structural redesign of LPS upon
exposure to changing environmental conditions or enve-
lope stress factors. As shown for E. coli K-12, modification
of lipid A with P-EtN occurs under certain conditions
such as in response to external stimuli like ammonium
Figure 4 Structures and molecular masses of lipid IVA molecules identified by ESI FT-ICR mass spectrometry in BL21 (DE3)-derived KPM mutants.
The ESI FT-ICR mass spectra are shown in Figure 3. Modifications of lipid IVA with palmitate (green) and P-EtN (magenta) are catalyzed by PagP
and EptA, respectively.
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appears to be transferred predominantly to the 1-
phosphate group of lipid A [31], double P-EtN substitu-
tions at the 1- und 4′-phosphate positions were evident in
lipid A of E. coli K-12 lacking LpxT activity [32] and lipid
IVA of a mutant strain defective in MsbA-dependent
translocation of LPS across the inner membrane [12].
Based upon ESI FT-ICR analysis presented here, deletion
of the eptA gene was clearly necessary as well as sufficient
to prevent lipid IVA of KPM404 from being substituted
with one or two P-EtN residues. Thus, our data not only
corroborate previous findings on the ability of EptA to
transfer P-EtN to both the 1- and the 4′-phosphate group
of lipid A [32], but also provide experimental evidence for
its ability to use lipid IVA as a substrate for single and
double P-EtN modifications.
In contrast to the E. coli K-12 strain KPM318, integra-
tion of lipid IVA into the outer membrane of KPM404 did
not result in a temperature-sensitive phenotype of the
BL21 (DE3)-derived mutant (data not shown). Although
closely related at the genomic level [33], combined ana-
lysis of the genomes, transcriptomes, proteomes and phe-
nomes of E. coli K-12 and BL21 (DE3) revealed significant
differences in their cellular physiology and metabolism
[34], which may explain the differences in the ability of
KPM318 and KPM404 to maintain outer membrane
integrity in the presence of lipid IVA at temperatures
above 40°C.Biological activity of engineered E. coli cells and LPS
To test the endotoxic potential of the engineered E. coli
K-12 and B strains, we performed TLR4/MD-2 activation
assays using HEK-Blue hTLR4 cells. Stimulation of these
cells, which express human TLR4, MD-2 and CD14 on
their surfaces, induces the production of the NF-κB- and
activator protein-1 (AP-1)-dependent reporter secreted
embryonic alkaline phosphatase (SEAP). The phosphatase
levels can be determined by reading the absorbance at
655 nm using a colorimetric substrate. In order to address
the question of whether NF-κB is specifically induced via
the hTLR4/MD-2 signaling pathway, HEK-Blue Null2
cells, the parental cell line of HEK-Blue hTLR4 cells lack-
ing the hTLR4/MD-2 receptor complex, were used as a
control in all hTLR4/MD-2 activation assays. The strains
KPM318, KPM335 and KPM404 as analyzed by challen-
ging HEK-Blue hTLR4 cells with an increasing number of
colony forming units (cfu) of up to 106 cfu/ml were virtu-
ally free of hTLR4/MD-2-stimulating activity, whereas
their parental strains BW30270 and BL21 (DE3) elicited a
substantial hTLR4/MD-2 activation already at 103 cfu/ml
(Figures 5A, B, 6A and B). When the extracted LPS of the
strains was subjected to the TLR4-specific assay, we could
confirm the lack of endotoxic activity of the samples iso-
lated from KPM318, KPM335 and KPM404 (Figures 5C,
D, 6C and D). The data also demonstrated that palmitoy-
lation of lipid IVA (when PagP was expressed) and/or
modification of lipid IVA with one or two P-EtN groups
Figure 5 Dose–response curves of NF-κB induction by whole bacterial cells and LPS of E. coli K-12 strains. The samples were assayed with HEK-Blue
hTLR4 cells for hTLR4/MD-2-mediated NF-κB induction by colorimetric determination of NF-κB-dependent SEAP activity (A and C). HEK-Blue Null2 cells,
the parental cell line of HEK-Blue hTLR4 cells lacking the hTLR4/MD-2 receptor complex, were used as a control (B and D). HEK-Blue hTLR4 and Null2
cells were stimulated with tenfold serial dilutions of whole bacterial cells (A and B) and LPS extracts (C and D) of KPM318 and KPM335 in comparison
to their parental strain BW30270, respectively. The values represent the means and standard deviations from three individual experiments. In
all experiments, assayed samples showed low level stimulation of HEK-Blue Null2 cells, indicating that NF-κB-dependent SEAP expression
was specifically induced via the hTLR4/MD-2 signaling pathway in HEK-Blue hTLR4 cells.
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KPM402 are capable of conferring certain hTLR4/MD-2
stimulatory activity on the otherwise endotoxically inactive
tetraacylated lipid A precursor (Figure 6). Our results allow
us to draw the major conclusion that inactivation of regu-
lated lipid IVA modifications as demonstrated herein to be
present in BL21 (DE3)-based intermediate mutant strains
is a crucial prerequisite to yield consistently endotoxin-free
E. coli strains.
As one of the critical mediators induced in response to
endotoxin, we assayed the release of TNF-α upon stimula-
tion of human macrophages by lipid IVA samples of
KPM318, KPM335 and KPM404. The samples exhibited
very low biological activity as demonstrated by their low
capacity to provoke TNF-α production in human macro-
phages even at concentrations of 0.1-1 μg/ml (Figure 7A).
Compared to the LPS from the parental strains, which in-
duced maximal TNF-α release at 0.01 μg/ml, TNF-α in-
duction was reduced by about 80-95% even at 100-foldhigher levels of mutant extracts. The well-documented
ability of lipid IVA to act as an antagonist for the hTLR4/
MD-2 signaling pathway [35,36] prompted us to examine
the inhibition of the agonistic activity of S-form LPS from
Salmonella enterica subspecies enterica serovar Abortuse-
qui (S. Abortusequi) by lipid IVA samples from KPM318,
KPM335 and KPM404. As shown in Figure 7B, pre-
exposure of macrophages to 0.1 μg/ml and 1 μg/ml of the
lipid IVA extracts resulted in 72.0 ± 11.2% and 75.9 ± 2.0%
(mean percent inhibition ± SD) inhibition of TNF-α pro-
duction induced by LPS from S. Abortusequi, respectively.
Thus, lipid IVA from KPM318, KPM335 and KPM404 dis-
played potent antagonistic activity against biologically ac-
tive wild-type LPS.
Endotoxin-free expression of ApoA-1 and Hsp70
Previous studies have shown that a BL21 (DE3) ΔlpxM::cat
mutant synthesizing a non-myristoylated LPS can be used
to express heterologous proteins with reduced stimulatory
Figure 6 Dose–response curves of NF-κB induction by whole bacterial cells and LPS of E. coli BL21 (DE3) strains. The samples were assayed with
HEK-Blue hTLR4 (A and C) and Null2 (B and D) cells for relative NF-κB induction by colorimetric determination of NF-κB-dependent SEAP activity.
Relative NF-κB induction was measured following stimulation of HEK-Blue hTLR4 and Null2 cells with tenfold serial dilutions of whole bacterial
cells (A and B) and LPS extracts (C and D) of E. coli BL21 (DE3) and BL21 (DE3)-derived KPM mutants, respectively. The values represent the
means and standard deviations from three individual experiments. In all experiments, assayed samples displayed negligible activation of parental
HEK-Blue Null2 cells, suggesting specific induction of NF-κB-dependent SEAP expression via the hTLR4/MD-2 signaling pathway in
HEK-Blue hTLR4 cells.
Figure 7 Biological activity of LPS from KPM mutants in human macrophages. Macrophages were differentiated from human blood monocytes
of healthy donors. On day seven of differentiation, macrophages were seeded at 1 × 105 cells/well and stimulated with LPS at the indicated
amounts (LPS from S. Abortusequi, BW30270 and BL21 (DE3) at 0.01 μg/ml; LPS from strains KPM318, KPM335 and KPM404 at 0.1 μg/ml and
1 μg/ml, respectively) for 4 h at 37°C (A). To determine the antagonistic activity of LPS from KPM strains, macrophages were incubated with LPS
samples from KPM318, KPM335 or KPM404 at 0.1 μg/ml or 1 μg/ml for 30 min at 37°C, followed by stimulation of the cells with 0.01 μg/ml of LPS
from S. Abortusequi for 4 h (B). Cell-free supernatants were analyzed for TNF-α content by ELISA. The values represent the means and standard
deviations from three independent experiments using cells from different donors.
Mamat et al. Microbial Cell Factories  (2015) 14:57 Page 8 of 15
Mamat et al. Microbial Cell Factories  (2015) 14:57 Page 9 of 15activity in human LPS-responsive cells [37]. To test the
ability of KPM318, KPM335 and KPM404 to serve as hosts
for the production of endotoxin-free recombinant proteins,
we selected the heterologously expressed human proteins
ApoA-1 and Hsp70 as model systems. ApoA-1, a major
component of high-density lipoprotein and important me-
diator in maintaining cholesterol homeostasis [38], is par-
ticularly challenging because the 28-kDa protein is known
to be directly involved in neutralization of LPS toxicity
and, therefore, difficult to separate from endotoxic activity
[39,40]. Yet another challenging protein able to associate
with LPS is Hsp70 [41]. Moreover, the 70-kDa molecular
chaperone has been suggested to function as an endogen-
ous damage-associated molecular pattern protein for acti-
vation of the TLR4 signaling pathway upon tissue injury
[42]. As Hsp70-induced stimulation of innate immune sys-
tem cells in many respects resembles the effects of LPS, re-
moval of endotoxin contamination, as frequently present
in recombinant Hsp preparations [43], remains a key issue
to discriminate between LPS- and Hsp-induced effects.
For production of ApoA-1, we used the T5 promoter-based
plasmid pApo404 in E. coli strains BW30270, KPM318 and
KPM335, whereas Hsp70 was expressed from pHsp70His
under the control of a T7 promoter in BL21 (DE3) and
KPM404. SDS-PAGE analysis of the protein samples
following minimal purification of each soluble protein
extract, by immobilized metal affinity chromatography
(IMAC), revealed that the endotoxin-free strains KPM318/
pApo404, KPM335/pApo404 and KPM404/pHsp70HisFigure 8 SDS-PAGE gels of ApoA-1 and Hsp70. The proteins were expresse
(DE3) (B), respectively, and minimally purified using IMAC on HisTrap HP (1
were resolved under denaturing conditions using 12% and 10% polyacryla
in lanes M. Arrows indicate the positions of ApoA-1 and Hsp70.produced recombinant ApoA-1 and Hsp70 in approxi-
mately equal quantities and had similar impurity profiles
as their parental strains, respectively (Figure 8). Since
ApoA-1 has been described to also associate with proteins
of the host cell [44], it was not surprising to detect rela-
tively high levels of protein contaminants in the IMAC-
purified ApoA-1 samples. Regardless, we did not perform
any further protein purification or endotoxin removal steps
to investigate the biological activity of the ApoA-1 and
Hsp70 samples.
The first test of biological activity employed was the
Limulus amebocyte lysate (LAL) assay, an FDA-approved
method that is based on activation of a coagulation cas-
cade in the LAL by trace amounts of endotoxin [45]. In
this assay, the endotoxin unit equivalents determined in
ApoA-1 samples from KPM318/pApo404 and KPM335/
pApo404 were significantly reduced by 92.7 ± 1.3% and
82.2 ± 3.9% (mean percent inhibition ± SD) compared to
those found in the ApoA-1 sample from BW30270/pApo404,
respectively (Figure 9). Furthermore, when KPM404/
pHsp70His was used as a host for production of Hsp70,
the LAL response to the protein decreased by 97.2 ± 0.5%
in comparison to the response elicited by Hsp70 obtained
from BL21 (DE3)/pHsp70His. The LAL assay, though
widely used for the detection and quantitation of endo-
toxins, is an inappropriate method to discriminate between
endotoxically active hexaacylated LPS and endotoxi-
cally inactive tetraacylated lipid IVA due to the presence
of the LAL-activating 4′-monophosphoryl-diglucosamined in endotoxin-free derivatives of E. coli strains BW30270 (A) and BL21
ml) columns. The recombinant ApoA-1 and Hsp70 samples (6 μg each)
mide gels, respectively. Molecular mass protein markers (kDa) were run
Figure 9 Reactivity of ApoA-1 and Hsp70 in the Limulus amebocyte
lysate (LAL) assay. ApoA-1 was produced in E. coli strain BW30270/
pApo404 and its endotoxin-free derivatives KPM318/pApo404 and
KPM335/pApo404, whereas Hsp70 was obtained from KPM404/
pHsp70His and its parental strain BL21 (DE3)/pHsp70His. The proteins
were minimally purified by IMAC and assayed with the LAL test. The
measurements represent the means and standard deviations from
three individual experiments.
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LAL clotting cascade is activated by a wider spectrum of
LPS/lipid A variants than LPS-responsive cells of the hu-
man immune system. The residual LAL reactivity of the
proteins from the lipid IVA host strains most likely reflects
the non-specific nature of the assay, giving rise to false
positive endotoxic results.
In order to specifically address the endotoxic activity of
the ApoA-1 and Hsp70 samples, we utilized the HEK-
Blue hTLR4/MD-2 cell activation assay. The ApoA-1 and
Hsp70 samples derived from the endotoxin-free strains
did not trigger an endotoxic response in HEK-Blue hTLR4
cells, even when present in the assay at 10 μg/ml, whereas
the proteins produced in the parental strains showed sub-
stantial NF-κB activation already at concentrations in the
range between 0.1 μg/ml and 1 μg/ml (Figure 10). These
results were in excellent agreement with the inability of
KPM318, KPM335 and KPM404 cells and LPS to stimu-
late the hTLR4/MD-2 signaling pathway (Figures 5 and 6).
As exemplified herein by heterologous expression of
ApoA-1 and Hsp70, proteins prepared from engineered
E. coli strains are innately free of endotoxic activity in
human LPS-responsive cells, consistent with earlier
observations that KPM335 is also a suitable host forproduction of functional endotoxin-free inclusion bodies
of the aggregation-prone fluorescent fusion protein
VP1GFP [48]. However, it must be taken into account
that lipid IVA may act agonistically in other mammalian
hosts such as mouse [49], Chinese hamster [50] or equine
[36] cells, which reflects species-specific lipid IVA sensing
by the TLR4/MD-2 complex [51,52]. The application of
proteins in cells other than human cells may therefore also
require lipid IVA depletion. Due to the lack of specificity,
the LAL assay cannot be used to assess endotoxic activity
but is ideally suited to detect residual lipid IVA in recom-
binant proteins prepared from LPS-free E. coli strains. We
are aware that we currently cannot respond to the ques-
tion of whether further purification of ApoA1 and Hsp70
would result in complete loss of lipid IVA. However, our
data on significantly decreased LAL reactivities of min-
imally purified ApoA1 and Hsp70 proteins from endotoxin-
free bacteria give reason to assume that lipid IVA, being
homogeneous, is much easier to remove from downstream
products than mature LPS. Despite a common backbone
structure, LPS is synthesized as a heterogeneous mixture of
structurally related molecules that are decorated with vari-
ous substituents, usually present in non-stoichiometric
amounts [53]. These substitutions, which may vary signifi-
cantly depending on growth conditions, contribute to con-
siderable physico-chemical heterogeneity of LPS molecules,
posing a major challenge to the development of a generally
applicable method for endotoxin removal from proteins
produced in common E. coli expression strains [5].
Conclusions
Recombinant proteins manufactured in E. coli are inher-
ently contaminated with endotoxin. In light of the enor-
mous diversity of recombinant proteins expressed in E.
coli, none of the purification methods are universally ap-
plicable to significantly reduce the endotoxin content.
Instead of removing endotoxin from the protein sam-
ples, the work presented here demonstrates that it is
now possible to eliminate endotoxin at the source by
producing proteins in an endotoxin-free environment
using LPS-free derivatives of E. coli K-12 and BL21
(DE3) strains. These non-conditional mutants clearly
lack hTLR4/MD-2 signaling pathway agonists yet can re-
tain viability through predominantly synthesizing the
tetraacylated, endotoxically inactive lipid A precursor
lipid IVA. The design of the strains also prohibits them
from easily regaining the potential to synthesize normal
LPS or endotoxically active lipid IVA derivatives through
acquiring mutations. This has been accomplished by
incorporating a total of seven non-reverting genetic
deletions that disrupt Kdo biosynthesis and prevent lipid
IVA from being modified with enzymes of both the consti-
tutive and the regulated LPS pathway, while the compen-
sating mutations msbA52 and msbA148 enable the E. coli
Figure 10 Stimulation of hTLR4/MD-2 by ApoA-1 and Hsp70 produced in endotoxin-free E. coli strains. The proteins were minimally purified by
IMAC and assayed with HEK-Blue hTLR4 cells for their ability to activate NF-κB-dependent SEAP expression (A and C). HEK-Blue Null2 cells served
as a control (B and D). Relative NF-κB induction was measured following stimulation of HEK-Blue hTLR4 and Null2 cells with tenfold serial dilutions of
ApoA-1 (A and B) and Hsp70 (C and D) samples obtained by heterologous expression in BW30270/pApo404, KPM318/pApo404 and KPM335/
pApo404, and BL21 (DE3)/pHsp70His and KPM404/pHsp70His, respectively. The values represent the means and standard deviations from three
individual experiments. In all experiments, the ApoA-1 and Hsp70 samples did not activate NF-κB-dependent SEAP expression in HEK-Blue
Null2 cells, suggesting that NF-κB-dependent SEAP expression was due to specific activation of the hTLR4/MD-2 signaling pathway in HEK-Blue
hTLR4 cells.
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respectively. The derivation of E. coli strains with dramat-
ically modified LPS affords the unique opportunity to pro-
duce endotoxin-free recombinant proteins suitable for
downstream experiments with human cells. These strains
allow researchers to save time-consuming cleanup steps
that may affect yield and functionality of the end product.
Methods
Bacterial strains, plasmids and growth conditions
All strains and plasmids used in the present study are
described in Additional file 4: Table S4. The bacteria
were grown aerobically with shaking (220 rpm) at 37°C
in standard LB-Miller medium containing 10 g/l of NaCl
to maintain a non-mucoid phenotype in ΔKdo strains
[54]. To induce LPS biosynthesis and restore susceptibil-
ity of Kdo-depleted KPM strains to phage P1vir, the
media was supplemented with 15 μM D-arabinose 5-phosphate and 10 μM D-glucose 6-phosphate [11,12].
Ampicillin (100 μg/ml), carbenicillin (200 μg/ml), kana-
mycin (30 μg/ml) or chloramphenicol (30 μg/ml) was
added to the media as required.
DNA manipulations
Chromosomal deletions were constructed with the
phage λ Red recombinase system [55] using the plasmids
pKD4 and pKD3 as templates for amplification of the
kanamycin and chloramphenicol resistance cassettes, re-
spectively (for targeting cassette primers see Additional
file 2: Table S2). To prevent insertion of the targeting
cassettes into scar sequences of previously deleted genes,
the insert cassettes targeting the lpxM, pagP, lpxP and
eptA genes were generated first in separate donor strains
and then transferred successively to the KPM strains by
P1vir transduction according to standard protocols [56].
The P1vir donor strains were constructed by the phage
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was generated using the “Gene doctoring” method [57].
The kanamycin resistance cassette targeting the lpxM gene
of BL21 (DE3) was amplified from pDOC-K with targeting
cassette primers DOCBL21lpxMH1 and DOCBL21lpxMH2,
digested with EcoRI/SpeI and ligated into the EcoRI/SpeI
sites of pDOC-C to yield pDOClpxM::kan. The lpxM gene
was then replaced with lpxM::kan by co-transformation of
BL21 (DE3) with pDOClpxM::kan and the recombineering
plasmid pACBSCE as described [57]. Unmarked deletion
mutants were obtained by excision of the antibiotic resist-
ance markers in the presence of the FLP recombinase
encoded either by pCP20 [55] or pFLP2 [58], followed by
curing of the helper plasmids at 37°C or sucrose selection,
respectively. All strains were tested for loss of the relevant
genes by PCR (for control primers see Additional file 2:
Table S2). The nonconditional suppressor strain KPM22
L11 maintaining the normally lethal ΔgutQ and ΔkdsD
mutations [12] was used as the parent for construction of
KPM strains with the E. coli K-12 genetic background.
Strain KPM318, showing temperature-sensitive growth
defects at temperatures above 40°C, was adapted to ele-
vated temperatures by continued propagation of the bac-
terial cells at 42°C, which yielded strain KPM335 capable
of sustained growth at 42°C.
To convert E. coli BL21 (DE3) into a nonconditional
suppressor strain able to tolerate null mutations in essen-
tial Kdo pathway genes, the wild-type msbA gene of the
strain was replaced by the msbA148 allele, which was pre-
viously identified as a suppressor of the lethal phenotype
associated with Kdo depletion in E. coli KPM22 L1 [12].
Using the primers 5ECycaI and 3ECycaQ (Additional
file 2: Table S2), msbA148 was amplified from the E.
coli KPM22 L1 suppressor strain. A kanamycin resistance
cassette targeting the essential msbA wild-type gene was
generated as reported [12] and inserted into the chromo-
some of BL21 (DE3) containing the temperature-sensitive
helper plasmids pKD46 [55] and pMAK705-ECmsbA.
The latter plasmid was constructed by amplification of
the msbA gene of E. coli BW30270 with primer pair
5HindIIIECmsbA/3BamHIECmsbA (Additional file 2:
Table S2), digestion of the PCR product with HindIII/
BamHI and cloning into the HindIII/BamHI sites of
pMAK705 [59]. After transformation of E. coli BL21 (DE3)
ΔmsbA::kan/pKD46/pMAK705-ECmsbA with msbA148,
screening for replacement of the ΔmsbA::kan cassette by
the suppressor allele was performed at 37°C to select for
transformants that retained viability upon loss of the func-
tional copy of the msbA wild-type gene encoded on the
temperature-sensitive plasmid pMAK705-ECmsbA. The
successful insertion of msbA148 was then verified by PCR
amplification and sequence analysis. As a result, the strain
E. coli MWB03 was obtained, which subsequently served
as the host for deletion of Kdo/lipid A genes.The plasmid pApo404 carrying the synthetic gene with
optimized E. coli codon usage for expression of human
ApoA-1 as a C-terminally histidine-tagged fusion protein
was manufactured by DNA2.0, Menlo Park, CA. The
codon-optimized gene for human Hsp70 was synthesized
by GenScript, Piscataway, NJ, digested with NdeI and
HindIII, and ligated into the NdeI/HindIII sites of
pET-22b to yield plasmid pHsp70His.
Whole-genome sequencing and data analysis
The genomes of strains BW30270, KPM318 und KPM335
were sequenced at the Scripps Research Institute on
the Illumina HiSeq instrument after library preparation
with a customized protocol. Genomic DNA samples were
sheared to a size range between 200 and 300 bp using an
S2 Covaris ultrasonicator. The fragments were then end
repaired, A-tailed with Taq polymerase, phosphorylated
and ligated to standard Illumina TruSeq barcoded adapters
following Illumina recommended protocols. The libraries
were then PCR amplified for 12 cycles, followed by gel
purification of the amplified libraries to select insert sizes
between 200 and 250 bp.
For strains BL21 (DE3) and KPM404, the genomic DNAs
were sequenced at the Research Center Borstel using the
Illumina MiSeq sequencer, Nextera XT library preparation
kits, and 500 cycle v2 sequencing kits as instructed by the
manufacturer. Resulting reads were mapped to the genome
of either E.coli K-12 MG1655 [GenBank:NC_000913.2] for
strains BW30270, KPM318, and KPM335, or E. coli BL21
(DE3) [GenBank:CP001509.3] for strains BL21 (DE3) and
KPM404, using the exact alignment program SARUMAN
[60]. Single nucleotide polymorphisms and Indels were ex-
tracted from mapped reads by customized Perl scripts
using a minimum coverage of ten reads and a minimum
allele frequency of 75% as thresholds for detection.
The whole-genome sequence data of this study have
been submitted to the NCBI Sequence Read Archive
[SRA:PRJNA212553].
LPS and lipid IVA isolation and characterization
The dried biomasses of stationary phase 2-liter cultures
were used to isolate either LPS by the original phenol/
chloroform/light petroleum (PCP) procedure [61] or
lipid IVA by a modified PCP protocol [12]. For ESI FT-
ICR, the samples were prepared as described previously
[62]. The mass spectra were recorded in the negative ion
mode using a 7-Tesla hybrid Apex Qe Instrument (Bruker
Daltonics).
Overexpression and purification of human ApoA-1 and
Hsp70
Each strain was grown to an OD600 of 0.6 - 0.7 before
the heterologous protein was expressed in the presence
of 0.4 mM isopropyl-β-D-thiogalactoside for 3 h. All
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harvested by centrifugation at 9,000 × g for 20 min,
washed with phosphate-buffered saline, re-suspended in
45 ml of 25 mM Tris–HCl, pH 7.5, 0.1 M NaCl, and in-
cubated with lysozyme (0.2 mg/ml) for 30 min and con-
tinuous stirring. Prior to disintegration of the cells by three
passages through a French pressure cell at 20,000 psi, the
suspension was supplemented with DNase I (50 μg/ml),
RNase A (50 μg/ml) and Complete Protease Inhibitor
Cocktail (EDTA-free) according to the recommendations
of the manufacturer (Roche), followed by centrifugation of
the lysate at 10,000 × g for 30 min to remove cellular deb-
ris. Imidazole was added to a final concentration of 10 mM
before the cleared lysate was loaded onto a HisTrap HP
(1 ml) column (GE Healthcare) pre-equilibrated with
25 mM Tris–HCl, pH 7.5, 0.1 M NaCl, 10 mM imidazole.
The column was extensively washed with a stepwise gradi-
ent of 20 mM, 80 mM and 100 mM imidazole in 25 mM
Tris–HCl, pH 7.5, 0.1 M NaCl, and the heterologously
expressed protein was eluted using 500 mM imidazole in
the same buffer. Fractions containing the protein were
pooled and dialyzed against 25 mM Tris–HCl, pH 7.5,
0.1 M NaCl.
Protein samples were separated by sodium dodecylsul-
fate polyacrylamide gel electrophoresis (SDS-PAGE) [63]
and visualized by staining with Coomassie Brilliant Blue
R-250.
Toll-like receptor activation assays
The stimulation assays using whole bacterial cells, ex-
tracted LPS samples and heterologously expressed hu-
man proteins were performed with HEK-Blue™ hTLR4
and HEK-Blue™ Null2 cells in accordance with the speci-
fications of the supplier of the cell lines (InvivoGen).
The HEK-Blue hTLR4 cells were grown at 37°C in a hu-
midified atmosphere with 5% CO2 in Dulbecco’s modi-
fied Eagle’s medium (DMEM) containing 4.5 g/l glucose
(PAA Laboratories), 2 mM L-glutamine (PAA Laboratories),
10% fetal bovine serum, PAA Clone (PAA Laboratories),
100 μg/ml Normocin™ (InvivoGen), 1 × HEK-Blue™
Selection solution (InvivoGen), and 1 × penicillin-streptomycin
(Pen-Strep) solution (PAA Laboratories). The parental cell
line of HEK-Blue hTLR4, HEK-Blue Null2, was grown
under the same conditions in DMEM supplemented
with 4.5 g/l glucose, 2 mM L-glutamine, 10% fetal bo-
vine serum, PAA Clone, 100 μg/ml Normocin, 100 μg/ml
Zeocin™ (InvivoGen), and 1 × Pen-Strep solution. When a
60-80% confluency was reached, the cells were detached
in the presence of Dulbecco’s phosphate-buffered saline
(DPBS) (PAA Laboratories), washed with DPBS and resus-
pended at a cell density of 1.4 × 105 cells/ml in HEK-Blue
test medium consisting of DMEM with 4.5 g/l glucose,
2 mM L-glutamine, 10% fetal bovine serum, PAA Clone,
100 μg/ml Normocin, and 1 × Pen-Strep solution. Forstimulation of HEK-Blue cells, each sample (20 μl) was
mixed with 180 μl of the cell suspension (25,000 cells) in
one well of a 96-well plate (COS96ft - Corning 96 Flat
Bottom Transparent Polystyrol) and incubated at 37°C for
20 h in a humidified atmosphere with 5% CO2. The super-
natant of each HEK-Blue cell suspension (20 μl) was then
added to 180 μl of reconstituted QUANTI-Blue™ substrate
(InvivoGen) per well, followed by incubation of the sam-
ples at 37°C for 3 h. NF-κB-dependent SEAP activity was
determined by reading the absorbance at 655 nm using a
Tecan Infinite M200 NanoQuant Microplate Reader. The
positive and negative control reactions were prepared with
25,000 HEK-Blue cells per well and assayed under the
same conditions as described above. For the positive con-
trol experiments, tenfold serial dilutions of LPS from E.
coli K-12 (InvivoGen) and recombinant human TNF-α
(200 ng/well) (InvivoGen) were used. To determine the
basal levels of SEAP activity, pyrogen-free water, 10 × con-
centrated Pen-Strep in DPBS, and 25 mM Tris–HCl,
pH 7.5, 0.1 M NaCl, served as negative controls to assay
LPS samples, whole bacterial cells and heterologously
expressed proteins, respectively. The basal level of SEAP
activity in untreated HEK-Blue cells was subtracted from
the relative SEAP activity measured for each treated
sample.
Whole bacterial cells were prepared for the assays from
aliquots of overnight cultures. The cells were sedimented
by centrifugation, washed with DPBS, re-suspended in a
10 × concentrated Pen-Strep solution in DPBS, and incu-
bated first at 22°C for 3 h and then at 4°C overnight.
On the basis of CFU counts obtained from platings
of the initial overnight cultures, the Pen-Strep-treated
cells were serially diluted appropriately in 10 × concen-
trated Pen-Strep in DPBS. Serial dilutions of LPS and pro-
tein samples were performed in pyrogen-free water and
25 mM Tris–HCl, pH 7.5, 0.1 M NaCl, respectively.
Activation of human macrophages
Biological activity of LPS was tested on human macro-
phages derived from blood of healthy donors. The Ethics
Committee of the University of Lübeck, Germany, ap-
proved the procedures. Monocytes were isolated, differenti-
ated to macrophages and stimulated with LPS samples as
described [64]. Briefly, MNCs were cultivated in teflon bags
in RPMI medium supplemented with 200 mML-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin, 4% heat-
inactivated human serum type AB and 2 ng/ml macro-
phage colony-stimulating factor (R&D Systems, Wiesbaden,
Germany) at 37°C for 7 days in a humidified atmosphere
with 5% CO2. Macrophages were harvested on day 7,
washed twice in serum-free RPMI, and seeded in serum-
free RPMI containing 200 mM L-glutamine, 100 U/ml
penicillin and 100 μg/ml streptomycin for experiments.
After 4 h of stimulation with LPS, TNF-α was determined
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set according to the recommendations of the manufac-
turer (BD Biosciences). Lyophilized LPS samples were
re-suspended in pyrogen-free water at 1 mg/ml stock
by sonication for 30 min and temperature-cycled twice be-
tween 4°C and 56°C. The samples were stored at least for
12 h at 4°C before biological experiments.
Limulus amebocyte lysate assay
The Limulus amebocyte lysate (LAL) assay was per-
formed using the Endosafe® Portable Test System (PTS)
with single-use Endosafe®-PTS cartridges as specified by
the supplier (Charles River Laboratories).
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